BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDY

  • S Leppa (Author)
  • J Jørgensen (Co-author)
  • ML Karjalainen-Lindsberg (Co-author)
  • Beiske K. (Co-author)
  • P. Nørgaard (Co-author)
  • K. Drott (Co-author)
  • Pasanen A (Co-author)
  • Karihtala K (Co-author)
  • Mannisto S. (Co-author)
  • Wold B (Co-author)
  • Brodtkorb M. (Co-author)
  • M Fagerli (Co-author)
  • Thomas Stauffer Larsen (Co-author)
  • Lars Munksgaard (Co-author)
  • Ø Fluge (Co-author)
  • S Jyrkkiö (Co-author)
  • Peter de Nully Brown (Co-author)
  • H. Holte (Co-author)

Activity: Talks and presentationsConference presentations

Period17. Jun 2021
Event titleInternational congress on malignant lymphoma ICML-16
Event typeConference
LocationLugano, Switzerland